Literature DB >> 14615659

Patterns and correlates of discontinuation of the initial HAART regimen in an urban outpatient cohort.

Megan E O'Brien1, Rebecca A Clark, C Lynn Besch, Leann Myers, Patricia Kissinger.   

Abstract

OBJECTIVES: To describe the patterns and correlates of discontinuation of the initial highly active antiretroviral therapy (HAART) regimen in an urban, outpatient cohort of antiretroviral-naive patients.
DESIGN: Retrospective cohort of 345 randomly selected antiretroviral-naive patients who initiated HAART on 6 selected regimens between January 1997 and May 2001 in New Orleans, LA.
METHODS: An investigator reviewed medical records to collect information on concurrent medications, symptoms/diagnoses, staging indicators, and reasons for HAART discontinuation. Proportional hazards regression methods were used to identify predictors of discontinuation.
RESULTS: After a median follow-up of 8.1 months, 61% of patients changed or discontinued their initial HAART regimen; 24% did so because of an adverse event. The events most commonly cited as the cause for discontinuation were nausea, vomiting, and diarrhea. A detectable viral load was associated with discontinuation at any time, while reporting nausea/vomiting or dizziness at the previous visit were associated with discontinuation during the first 3 months on HAART. Nausea/vomiting and not having AIDS at the time of HAART initiation were associated with discontinuation due to an adverse event at any time, while a high viral load, and dizziness or anorexia/weight loss at the previous visit were associated with discontinuation due to an adverse event in the first 3 months on HAART.
CONCLUSIONS: Gastrointestinal adverse events of HAART are the most frequently cited reason for discontinuation of HAART. An effort should be made to educate patients about these events and to encourage continued adherence. Additionally, appropriate prophylaxes for these events are warranted.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14615659     DOI: 10.1097/00126334-200312010-00008

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  69 in total

Review 1.  When to start antiretroviral therapy.

Authors:  Cunlin Wang; Saba W Masho; Daniel E Nixon
Journal:  Curr HIV/AIDS Rep       Date:  2006-07       Impact factor: 5.071

Review 2.  Translating efficacy into effectiveness in antiretroviral therapy: beyond the pill count.

Authors:  Courtney V Fletcher
Journal:  Drugs       Date:  2007       Impact factor: 9.546

Review 3.  Impact of metabolic complications on antiretroviral treatment adherence: clinical and public health implications.

Authors:  Jean B Nachega; Maria Paola Trotta; Mark Nelson; Adriana Ammassari
Journal:  Curr HIV/AIDS Rep       Date:  2009-08       Impact factor: 5.071

4.  Non-nucleoside reverse transcriptase inhibitor outcomes among combination antiretroviral therapy-treated adults in Botswana.

Authors:  C William Wester; Ann Muir Thomas; Hermann Bussmann; Sikhulile Moyo; Joseph M Makhema; Tendani Gaolathe; Vladimir Novitsky; Max Essex; Victor deGruttola; Richard G Marlink
Journal:  AIDS       Date:  2010-01       Impact factor: 4.177

5.  Acupuncture and the relaxation response for treating gastrointestinal symptoms in HIV patients on highly active antiretroviral therapy.

Authors:  Bei-Hung Chang; Elizabeth Sommers
Journal:  Acupunct Med       Date:  2011-06-24       Impact factor: 2.267

6.  Prevalence and Correlates of Reporting Difficulty Taking Antiretroviral Treatment Among HIV-Positive Illicit Drug Users in Vancouver, Canada: A Longitudinal Analysis.

Authors:  Bianca Yeung; N A Mohd Salleh; Eugenia Socías; Huiru Dong; J Shoveller; J S G Montaner; M-J S Milloy
Journal:  AIDS Behav       Date:  2019-05

7.  Factors associated with lack of antiretroviral adherence among adolescents in a reference centre in Rio de Janeiro, Brazil.

Authors:  L F B Filho; S A Nogueira; E S Machado; T F Abreu; R H de Oliveira; L Evangelista; C B Hofer
Journal:  Int J STD AIDS       Date:  2008-10       Impact factor: 1.359

8.  Proteomic analysis of PBMCs: characterization of potential HIV-associated proteins.

Authors:  Lijun Zhang; Xiaofang Jia; Xiaojun Zhang; Jianjun Sun; Xia Peng; Tangkai Qi; Fang Ma; Lin Yin; Yamin Yao; Chao Qiu; Hongzhou Lu
Journal:  Proteome Sci       Date:  2010-03-12       Impact factor: 2.480

9.  Rates and reasons for early change of first HAART in HIV-1-infected patients in 7 sites throughout the Caribbean and Latin America.

Authors:  Carina Cesar; Bryan E Shepherd; Alejandro J Krolewiecki; Valeria I Fink; Mauro Schechter; Suely H Tuboi; Marcelo Wolff; Jean W Pape; Paul Leger; Denis Padgett; Juan Sierra Madero; Eduardo Gotuzzo; Omar Sued; Catherine C McGowan; Daniel R Masys; Pedro E Cahn
Journal:  PLoS One       Date:  2010-06-01       Impact factor: 3.240

10.  Lack of a significant drug interaction between raltegravir and tenofovir.

Authors:  Larissa A Wenning; Evan J Friedman; James T Kost; Sheila A Breidinger; Jon E Stek; Kenneth C Lasseter; Keith M Gottesdiener; Joshua Chen; Hedy Teppler; John A Wagner; Julie A Stone; Marian Iwamoto
Journal:  Antimicrob Agents Chemother       Date:  2008-07-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.